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MaPeripartum cardiomyopathy (PPCM) is a pregnancy-associated myocardial disease with marked left ventricular systolic
dysfunction. Although this condition can lead to major complications, including severe heart failure, arrhythmias,
thromboembolic events, and death, the majority of women with this condition demonstrate a complete or partial
recovery. Many of these women desire to become pregnant again and are concerned regarding the safety of additional
pregnancies. The purpose of this paper is to review the available information related to subsequent pregnancies in
women with a history of PPCM in an attempt to reach conclusions regarding the risk of such pregnancies in this group of
patients. (J Am Coll Cardiol 2014;64:1629–36) © 2014 by the American College of Cardiology Foundation.P eripartum cardiomyopathy (PPCM), alsoknown as pregnancy-associated cardiomyopa-thy (1), is an uncommon condition in which an
idiopathic form of left ventricular (LV) systolic
dysfunction develops during pregnancy or the post-
partum (PP) period in women without previous heart
disease (2). The incidence of this condition in the
United States is approximately 1 in 3,000 deliveries,
with a signiﬁcantly higher incidence in African Amer-
icans, women older than 30 years of age, those with a
history of pregnancy-associated hypertension, and in
those with multifetal pregnancies (3). Higher inci-
dences have also been reported in countries outside
of the United States, particularly in Africa and in Haiti
(4). Although PPCM can be associated with important
complications, including severe symptomatic heart
failure (HF), malignant arrhythmias, thromboembolic
events, and death (5), the majority of women demon-
strate a partial or complete recovery within 2 to 6
months after the diagnosis (1,6). An analysis of >100
women with PPCM in the United States demonstrated
the development of PPCM in conjunction with their
ﬁrst or second pregnancy in more than half of them the Department of Medicine, Division of Cardiology, and the Depar
uthern California, Keck School of Medicine, Los Angeles, California. Dr.
evant to the contents of this paper to disclose.
nuscript received May 20, 2014; revised manuscript received June 17, 20cases (1). It is, therefore, not surprising that many
women with a history of PPCM desire to become preg-
nant again. The question of the risks of subsequent
pregnancies (SSPs) has been the most common reason
for consultation provided by us and by others to
women with a history of PPCM and physicians taking
care of such women (7). A recurring concern about
PPCM is the potential risk of SSP, even if LV function
returns to normal. Despite the critical importance of
this issue, it is only brieﬂy discussed in the most
recent guidelines for the management of pregnancy-
related heart disease (8).
REVIEW OF PUBLISHED CASES OF
SUBSEQUENT PREGNANCIES
Ostrzega and Elkayam (9) conducted an early survey
that relied solely on a questionnaire ﬁlled out by
physicians. This questionnaire provided data on 67
SSPs in 63 women who had PPCM, 40 of whom had
recovery of LV function and 23 of whom had persis-
tent LV dysfunction (Table 1). Twenty-three percent
of 43 pregnancies in women with normal LV functiontment of Obstetrics and Gynecology, University of
Elkayam has reported that he has no relationships
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1630were associated with worsening cardiac
function, and 1 (2%) resulted in death. The
women with persistent LV dysfunction had
24 SSPs, of which 13 (54 %) were associated
with cardiac dysfunction; 2 women (9%)
died. To conﬁrm the results of this survey
(published only as an abstract in 1995), the
same investigators conducted a second sur-
vey in 1997 and 1998 of approximately 15,000
American College of Cardiology members and
identiﬁed 60 well-documented SSPs in 44
women (23 white, 16 black, and 5 Hispanic)
with a history of PPCM (10). The patientswere divided into 28 women who recovered LV
function (LV ejection fraction $50%) before their SSP
(group 1) and 16 women who had persistent LV
dysfunction (group 2). The mean LV ejection fraction
(EF) decreased in both groups (Figure 1) in conjunc-
tion with pregnancy: from 56  7% to 49  10% in
group 1 (p ¼ 0.002) and from 36  9% to 32  11% inPost-partum
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sequent pregnancy. For group 2, p ¼ 0.05 for the com-
llow-up and the index pregnancy, and p ¼ 0.08 for the
t pregnancy and post-partum follow-up. Reprinted with
(10).group 2 (p ¼ 0.08). During the ﬁrst SSP, 21% of group 1
patients and 44% of group 2 had symptoms of HF
(Figure 2). Twenty-one percent of group 1 women and
25% of group 2 women had a substantial (>20%)
decrease in LVEF during pregnancy or during the PP
period, with a persistent decrease at the last follow-
up (90  87 months) in 14% of group 1 women and
31% of group 2 women (Figure 2). Although no mor-
tality occurred in group 1, it was reported in 3 women
in group 2 (19%). Two of these women died suddenly
(one 2 months and the other 2 years after the SSP),
and the third died of progressive HF 2 months PP.
Witlin et al. reported on 7 SSPs in 6 women with
PPCM (11). One patient with normal LV function had 2
SSPs without relapse. Another patient with persistent
LV dysfunction remained stable throughout her SSP
on HF therapy. The remaining 4 patients, who were
asymptomatic and clinically stable, had relapses with
deterioration of LV function and symptoms between
the 20th and 31st week of gestation.
Avila et al. reported no maternal complications in
6 SSPs with normal LV function and the development
of congestive HF in 30% of 11 patients with LV
dysfunction that was associated with pulmonary
embolism in 1 patient and death in another (12). Two
of the surviving patients had a >20% reduction in
their EF post-partum.
Sliwa et al. reported on 6 SSPs, 4 in women with a
LVEF <40% who were asymptomatic with unchanged
EF during pregnancy, but who developed HF symp-
toms and a >10% decrease in EF after the delivery
(13). In addition, 1 patient with normal LVEF before
pregnancy, who was stable at 1 month PP, had a later
deterioration. At 3 months post-delivery, 2 patients
with impaired EF at the onset of SSP died due to HF,
and the remaining 4 patients demonstrated persistent
LV dysfunction, with LVEF reduced to an average
of 25%.
Chapa et al. reported 8 SSPs, 4 of them after
recovery of LVEF. All 4 women with recovered LV
function became symptomatic and developed recur-
rent LV dysfunction in the third trimester that per-
sisted after pregnancy in 3 of them. Surprisingly, the
2 patients with persistent LV dysfunction had no
further change in EF or symptomatic deterioration
during the SSP (14).
Fett et al. reported on the outcome of 16 SSPs in
15 Haitian women with PPCM (15). All but 1 became
pregnant before complete recovery of LVEF. Eight
patients (53%) exhibited worsening HF, and 1 patient
(7%) died of severe HF 10 months PP. Only 1 of the
relapsed patients was reported to regain normal LV
function after pregnancy, whereas all patients
without relapse regained a normal EF over time.
TABLE 1 Outcome of Subsequent Pregnancy in Women With a History of
Peripartum Cardiomyopathy: Results of a Survey
Group
Maternal Outcome Fetal Outcome
No Relapse Relapse Death Live Birth Abortions Stillbirth
Group A 74.4% 23.3% 2.3% 93% 4.7% 2.3%
Group B 37.5% 54.2% 8.3% 83.3% 16.7% 0%
Values are %. Modiﬁed with permission from Ostrzega and Elkayam (9).
Group A ¼ women with recovered left ventricular function; Group B ¼ women with persistent left ventricular
dysfunction.
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FIGURE 2 Maternal Complications Associated With
Subsequent Pregnancy in 44 Patients With a History of
Peripartum Cardiomyopathy
Slate bars are group 1, women with left ventricular ejection fraction
(LVEF)$ 50%before subsequent pregnancy. Salmon bars are group
2,womenwithLVEF<50%beforesubsequentpregnancy.HF¼heart
failure. Reprinted with permission from Elkayam et al. (10).
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1631Habli et al. reported on 21 patients with PPCM with
at least partial recovery of LV function (average EF
47  9%). No mortality was reported, but 29% of pa-
tients exhibited worsening of HF related to their SSP,
and 2 patients required cardiac transplantation (16).
Modi et al. provided information on 13 SSPs, with
worsening of HF in all of them. No information was
provided on LV function before the SSP (17).
Hilﬁker-Kleiner et al. (18) reported on SSPs in 12
black African women with PPCM and persistent LV
dysfunction (LVEF 40% to 45%). Six women demon-
strated clinical deterioration, and 3 women died
within 4 months PP.80%
70%
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FIGURE 3 Rate of Relapse in 61 Peripartum Cardiomyopathy
Patients With SSP According to LVEF Level Before SSP
Reproduced with permission from Fett et al. (19). LVEF ¼ left
ventricular ejection fraction; SSP ¼ subsequent pregnancy.Fett et al. (19) published data on 12 prospectively
identiﬁed SSPs from a PPCM registry in Haiti
(12 pregnancies in 11 women) and 49 SSPs from an
Internet support group website in the United States.
Relapse of LV dysfunction or worsening HF symp-
toms were reported in 17% of women with
LVEF $55%, 33% of women with LVEF between 50%
and 54%, 37% of women with LVEFs between 45%
and 49%, and 67% of women with LVEF <45%
(Figure 3). Recovery of LVEF to pre-pregnancy levels
was observed in the majority (87.5%) of women with
LVEF $50% before the SSP, but in only 20% of those
with LVEF <50%. One death was reported 1 month PP
in a woman who started her SSP with a markedly
depressed LVEF of 25%.
In a small study in India, Mandal et al. (20) reported
on 6 SSPs, 5 of them after improvement of LVEF to
>45%. Two patients developed HF, and one of them
subsequently developed persistent cardiomyopathy.
The sixth patient had LV dysfunction before the SSP
and died while delivering a stillborn baby at 27 weeks’
gestation. Two PPCM patients with SSP were
described in a report from Malaysia by Chee (21); 1
woman had an early termination, and the second
woman delivered vaginally with a normal LVEF.
In the last several years, I have consulted on
several women with recovered LV function who pre-
sented with a substantial reduction in EF related to
SSP. Table 2 provides a short history of 3 of these
patients who presented with life-threatening com-
plications. These complications included cardiac
arrest, cardiogenic shock, ventricular arrhythmias,
and the need for aggressive therapies (e.g., electrical
cardioversion, temporary LV assist devices, and
implantable cardioverter deﬁbrillator).
In summary, the 2 largest studies with a total of 105
SSPs, with PPCMs mostly diagnosed in the United
States (10,19), demonstrated relapse with worsening
of symptoms and deterioration of LV function
in almost one-third of the cases. These data are
supported by several other reports on a smaller
number of patients (11–18,20,21). The risk of relapse
in patients with persistent LV dysfunction is
TABLE 2 Three Cases of Severe Complications Related to Subsequent Pregnancy in Women With Recovered Left Ventricular Function*
Case # Age, yrs
Obstetrical
History
1 22 G3P3 Patient had ventricular ﬁbrillation arrest 4 months PP, was successfully resuscitated, and developed cardiogenic shock due to severe
LV dysfunction (EF 15%), complicated by multiorgan failure. She was supported initially by an intra-aortic balloon and a tandem
heart pump, and gradually improved. Patient required long-term rehabilitation, which resulted in neurological improvement and
recovery of EF to 60% at 4.5 months.
2 41 G2P2 Ventricular ﬁbrillation arrest at 34th week of ﬁrst SSP, successfully resuscitated and stabilized with LVEF 20% on medical therapy.
Uncomplicated C-section delivery 1 week later, followed by tubal ligation, and ICD implantation for secondary prevention of sudden
death. Cardiac function recovered completely within a few months. ICD was removed 3 years later because of lead infection.
3 39 G4P3 First SSP complicated by a marked fall in EF and ventricular arrhythmias requiring prolonged antiarrhythmic therapy. EF normalized
before her second SSP, which was followed by the development of HF 1 week PP due to recurrent LV dysfunction (EF 25%). Hospital
course was complicated by ventricular ﬁbrillation treated successfully by electrical cardioversion. Because of inability to provide a life
vest, the patient was hospitalized for 2 months and was discharged home once EF was 35%.
*All patients were not on heart failure (HF) treatment during SSP.
EF ¼ ejection fraction; ICD ¼ implantable cardioverter deﬁbrillator; LV ¼ left ventricular; PP ¼ post-partum, SSP ¼ subsequent pregnancy.
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1632substantially higher than in patients who have
normalized LV function before SSP, and the risk ap-
proaches 50%, with a low likelihood of recovery after
pregnancy (Table 3). In addition to the risk of relapse,
which usually occurs in the last part of pregnancy or
the early PP period (11,13), symptomatic deterioration
during pregnancy in patients with persistent LV
dysfunction could also be due to the increased
hemodynamic burden of pregnancy.
Normalization of LV function after PPCM does not
guarantee an uncomplicated SSP; approximately 20%
of such patients are also at risk of moderate to severe
deterioration of LV function, which persists after
delivery in 20% to 50% of patients (10,13,14,19,21,22)
(Table 4). Although the likelihood of maternal death
seems to be low in women with recovered LV func-
tion, relapse of PPCM may be associated with a sub-
stantial, and at times, persistent reduction in
EF, potentially leading to life-threatening complica-
tions that include cardiogenic shock and arrhythmias.
These conditions require aggressive therapy, includ-
ing electrical cardioversion, temporary LV assistTABLE 3 Patients With Persistent Left Ventricular Dysfunction Befor
First Author (Ref. #) Year
No. of
Pregnancies
Deterioration o
LV Function
Elkayam (10) 2001 12 4 (33)
Avila (12) 2002 9 NA
Sliwa (13) 2004 4 4 (100)
Chapa (14) 2005 4 0 (0)
Fett (15) 2006 16 8 (50)
Habli (16) 2008 10 9 (53)
Hilﬁker-Kleiner (18) 2007 12 5 (42)
Fett (19)* 2010 26 10 (46)
Total 93 40/84 (48)
Values are n (%). *Most patients identiﬁed by an Internet support group of liv
thereforenot available.
Abbreviations as in Table 2.devices, implantable cardioverter deﬁbrillation im-
plantation, and prolonged hospitalization (Table 4)
(10,11,14,19,20,22).
The mortality rate, even in women with persistent
LV dysfunction before SSP, was reported to be low
(0% to 0.5%) in 3 studies in the United States
(14,16,17), but was as high as 25% in another U.S.
study (10) and even higher in South African women
(13,18). Although it is reasonable to assume that some
of the previously reported incidences of mortality
could be preventable with early detection and
aggressive contemporary management of LV
dysfunction (as was provided to the cases presented
in Table 4), the risk of SSP-related death remains a
major concern, especially in women with persistent
LV dysfunction.
OUTCOME IN PATIENTS WITH
MORE THAN 1 SUBSEQUENT PREGNANCY
Chapa et al. (14) reported on 1 woman with persistent
LV dysfunction (EF not provided) who had 3 SSPse Subsequent Pregnancy
f Symptoms of
Heart Failure
Persistently Decreased
LVEF at Follow-Up Death
6 (50) 5 (42) 3 (25)
4 (44) 2 (22) 1 (11)
4 (100) 2 (50) 2 (50)
0 (0) 4 (100) 0 (0)
8 (53) 7 (44) 1 (6)
NA 5 (29) 1 (6)
NA 6 (50) 3 (25)
NA 5 (80) 1 (0.4)*
22/45 (49) 36/93 (39) 11/67 (16)
ing patients with a history of peripartum cardiomyopathy; mortality rate was
TABLE 4 Patients With Normal Left Ventricular Function Before Subsequent Pregnancy
First Author (Ref. #) Year
No. of
Pregnancies
Deterioration of
LV Function
Symptoms of
Heart Failure
Persistently Decreased
LVEF at Follow-Up Death
Elkayam (10) 2001 23 4 (17) 6 (20) 2 (50) 0 (0)
Avila (12) 2002 6 NA 0 (0) NA 0 (0)
Sliwa (13) 2004 2 2 (10) 2 (100) 2 (100) 0 (0)
Chappa (14) 2005 4 4 (100) 4 (100) 3 (75) 0 (0)
Habli (16) 2008 21 NA 6 (28) NA 0 (0)
Chee (21) 2009 2 0 (0) 0 (0) 0 (0) 0 (0)
Fett (19)* 2010 35 8 (17) NA 1 (12) –
Mandal (20) 2010 5 NA 2 (40) 1 (50) 0 (0)
Total 98 18/66 (27) 20/63 (32) 9/71 (13) 0/63 (0)
Values are n (%). *Most patients in this study were identiﬁed by an Internet support group of living patients with history of peripartum cardiomyopathy; mortality rate
was therefore not available.
Abbreviations as in Table 2.
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1633without deterioration of LV function. Fett et al. (15)
reported on 1 patient who had 2 SSPs with wors-
ening HF that occurred after the second SSP, but not
after the ﬁrst SSP. The same investigators later re-
ported on 3 women who had 2 SSPs, 1 of whom
developed HF during the second pregnancy but not
during the ﬁrst pregnancy, and a second woman who
had 3 SSPs with relapse only during the third preg-
nancy (19). Elkayam et al. reported on 11 women
with 16 additional SSPs (10). Five women with normal
LV function had 1 additional SSP each, and 4 had
2 additional SSPs. Of those with persistent LV dys-
function, 1 patient had 1 additional pregnancy, and 1
woman had 2 additional pregnancies. None of these
women were reported to have symptoms of HF during
the later pregnancies. One woman with normal LV
function who showed no change in cardiac function
during the ﬁrst SSP had a substantial decrease in EF
from 55% to 40% during the second pregnancy, and
did not recover after a follow-up of 3 months. In
summary, this limited information suggests that 1
uneventful SSP cannot predict the risk of later preg-
nancies in women with a history of PPCM.
TERMINATION OF PREGNANCY
In the study reported by Elkayam et al. (10), the mean
LVEF decreased by 14% (49  12% to 42  14%;
p < 0.001) in 35 women who did not have abortions
compared with a decrease of only 7% in 9 women who
had abortions (from 46  13% to 43  11%; p ¼ 0.20).
Another study (16) that analyzed the outcome of SSPs
on the basis of the initial EF at the time of PPCM
diagnosis, and had limited information on cardiac
function before the SSP, reported worsening of car-
diac symptoms related to pregnancy without abortion
in 21% of 19 women with an initial EF >25% comparedwith what was described as, “No end stage cardiac
disease,” in all 8 women who underwent early abor-
tion. In cases with an initial EF of <25%, 2 patients
who did not have an abortion were placed on the
heart transplantation list, whereas only 5 of 8 women
were listed for heart transplantation among those
who underwent early abortion. Although these
available data are limited by the small number of
patients and lack of information regarding reasons for
termination, and are not sufﬁcient to establish ﬁrm
conclusions, it seems that in patients with severe LV
dysfunction, early termination of SSP may prevent
further deterioration.
FETAL OUTCOME
Limited information is available regarding the fetal
outcome of SSP in women with a history of PPCM. A
survey by Ostrzega and Elkayam (9) reported 93% live
births and 5% abortion rates in women with recov-
ered LV function compared with 83% and 17%,
respectively, in women with abnormal LV function. In
the second survey by the Elkayam et al. (10), 21 of 35
women who did not have an abortion had normal
vaginal delivery, and 14 women delivered by cesarean
section. Premature delivery occurred in 13% of
women with normal LV function before SSP and in
50% of patients with persistent LV dysfunction
(Figure 4).
CAN RELAPSE OF PERIPARTUM
CARDIOMYOPATHY IN SUBSEQUENT
PREGNANCY BE PREDICTED?
Available information suggests that the best predictor
for SSP-associated relapse is pre-pregnancy LVEF.
A normal contractile reserve measured by exercise
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FIGURE 4 Fetal Complications Associated With Subsequent
Pregnancy in Patients With Peripartum Cardiomyopathy
Slate bars ¼ women with LVEF $50% before subsequent
pregnancy. Salmon bars ¼ women with LVEF <50% before
SSP. Reprinted with permission from Elkayam et al. (10).
Abbreviations as in Figure 3.
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1634echocardiography was suggested as a potential pre-
dictor of a low likelihood of relapse in women with
normal LV function. This suggestion was made on the
basis of 8 women with recovered LVEF and normal
cardiac response to exercise who did not relapse
during SSP (19). However, this hypothesis was not
tested because no patients with an abnormal
response to exercise were included. Thus, this idea
remains unproven and cannot be used to predict the
outcome of SSP.
MONITORING SUBSEQUENT PREGNANCY. Because
of lack of prospective data, there are no established
protocols for monitoring women with SSP. My pro-
tocol includes a baseline echocardiogram and mea-
surement of B-type natriuretic peptide levels before
or in the early stages of SSP. This is followed by close
monitoring of symptoms throughout pregnancy, with
repeat echocardiograms at the end of the ﬁrst and
second trimester, as well as 1 month before delivery,
before discharge, 1 month after delivery, and at
any instance of symptom development. Echocardio-
graphic assessment of cardiac function and pulmo-
nary pressures, as well as measurement of B-type
natriuretic peptide levels, are helpful in differenti-
ating the signs and symptoms of HF from normal
pregnancy symptoms, which may be confusing.
Because of the limited information on long-term
outcomes in women with PPCM, no recommendations
can be made regarding continuation of HF therapy in
women with complete recovery of LV systolic func-
tion and the use of such therapy during SSP. Women
who are taking HF medications should ideallydiscontinue teratogenic drugs, such as angiotensin-
converting enzyme inhibitors and angiotensin re-
ceptor blockers at least 3 months before conception,
and the LVEF without these medications should
be re-evaluated before SSP. These drugs should
be substituted for a combination of hydralazine
and isosorbide dinitrate in women with LV systolic
dysfunction (3). Aldosterone antagonists like spi-
ronolactone (category C) have no reported terato-
genic effects in humans, but there is a concern
regarding reported antiandrogenic effects leading to
feminization in male rat fetuses and endocrine dys-
functions that persist into adulthood in both sexes
(23,24). There is a lack of human pregnancy experi-
ence with beta-blockers used to treat HF (carvedilol,
bisoprolol, and metoprolol succinate), which are all
risk category C; their effects on the fetus is unknown.
Metoprolol tartrate, which is also risk category C,
may be preferred because it has been more commonly
used in pregnancy for the management of hyperten-
sion, arrhythmias, mitral stenosis, and myocardial
ischemia (25). In addition, because nonselective beta-
blockade could facilitate uterine activity, the use of
beta-1-selective beta-blockers is generally preferred
during pregnancy (23).
Preliminary information suggests a potential
beneﬁcial effect of bromocriptine in women with SSP.
Hilﬁker-Kleiner et al. (18) reported on 6 women with
SSP who received bromocriptine in addition to stan-
dard therapy up to 3 months post-delivery (time of
initiation not provided), who were compared with 6
other women who received standard treatment alone.
Although the peripartum LVEF was similar in both
groups, all 6 women treated with bromocriptine sur-
vived and had preserved or increased LV function and
decreased LV dimensions at the 4-month observa-
tion. In contrast, LVEF in the non-bromocriptine–
treated group deteriorated, and 3 women died within
4 months. In addition, prolactin serum levels, which
were elevated >5-fold, returned to nonpregnant
levels within 14 days of treatment in women who
received bromocriptine. Although this report is
exciting, and is supported by animal studies and
small-scale human studies (26), it is limited by the
small number of patients evaluated and by the un-
usually high rate of cardiac deterioration and mor-
tality found in women on standard HF therapy. More
data will therefore be needed to further establish a
potential role for bromocriptine in preventing the
relapse that is associated with SSP.
BREASTFEEDING. No information is available re-
garding breastfeeding after SSP in women with a his-
tory of PPCM. However, 1 recent study reported
Careful and close monitoring
recommended
Peripartum Cardiomyopathy (PPCM)
(Idiopathic form of left ventricular [LV] 
systolic dysfunction develops
during pregnancy or post-partum)
PERSISTENT LV DYSFUNCTION
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in LV dysfunction
Increased morbidity 
and mortality with SSP
Premature delivery 
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COMPLETE RECOVERY
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to persistent LV dysfunction
~20% have a relapse
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CENTRAL ILLUSTRATION Risks in Subsequent Pregnancies in PPCM
Varied pathways for patients who develop an idiopathic form of left ventricular (LV)
systolic dysfunction during pregnancy or post-partum. PPCM ¼ peripartum
cardiomyopathy; SSP ¼ subsequent pregnancy.
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1635breastfeeding in 67% of women who were diagnosed
with PPCM without adverse effects (27). The American
Academy of Pediatrics recommends human milk for
all infants for whom breastfeeding is not contra-
indicated (28). For these reasons, clinically stable
women with a history of PPCM should not be discour-
aged from breastfeeding after SSP. Most of the drugs
used for the management of HF are classiﬁed by the
American Academy of Pediatrics as compatible with
breastfeeding (28). For beta-blockers, however, no
reports are available on the use of carvedilol or meto-
prolol succinate during human lactation; the use of
metoprolol tartrate may be preferred (29). Although
metoprolol is concentrated in breast milk, the
amount of the drug is very small (225 mg in 1,000 ml for
an oral dose of 200 mg/day). To further minimize
exposure, it has been suggested to refrain from
breastfeeding for 3 to 4 h after taking the last dose.
Information is available on the use of both captopril
and enalapril during human lactation; the amount of
these drugs that could be ingested by the infant is
negligible and most likely insigniﬁcant (29). The
excretion rate of spironolactone in breast milk is un-
known, and its activemetabolite, candrenone, is found
in a minute, clinically insigniﬁcant dose (0.2% of the
mother’s daily dose) (29).
SUMMARY AND CONCLUSIONS
Although information is somewhat limited, the
available data strongly suggest that SSP in women
with a history of PPCM is associated with a risk of
relapse. This risk is high in women with persistent LV
dysfunction before their SSP, who are also at risk of
deterioration due to the increased hemodynamic
burden of pregnancy. Almost 50% of such women
were reported to have deterioration of LV function
during or following pregnancy, potentially leading to
major morbidity and even mortality. The available
information also suggests an increased risk of pre-
mature delivery and abortions in women with
persistent LV dysfunction. Complete recovery of LV
function before the SSP is associated with better
prognosis, and most women are likely to have a
normal pregnancy. However, uneventful pregnancy
is not guaranteed, and approximately 20% will have a
relapse of PPCM associated with a substantial
decrease in LV systolic function. Although the rate of
recovery is relatively high and the incidence of
mortality is low, relapse of PPCM, even in this group,
may be associated with deterioration of LV func-
tion, congestive HF, arrhythmias, and the need for
aggressive therapy, including the use of temporary
and permanent devices (Table 2) (10,11,13,16,19). Inaddition, in some cases, the persistence of LV systolic
dysfunction (10,13,14,19,21) may have detrimental
long-term consequences. Although limited data sug-
gest that PPCM relapse occurs in late pregnancy or in
the PP period, earlier deterioration can also occur
(11). Careful and close monitoring is therefore rec-
ommended throughout pregnancy and the PP period
for the early detection and treatment of recurrent
PPCM and prevention of complications (Central
Illustration).
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